CPC A61K 35/747 (2013.01) [A61K 8/492 (2013.01); A61K 8/99 (2013.01); A61K 9/0014 (2013.01); A61K 35/741 (2013.01); A61K 35/744 (2013.01); A61P 17/00 (2018.01); A61P 31/04 (2018.01); A61Q 17/04 (2013.01); A61Q 19/08 (2013.01)] | 19 Claims |
1. A method of treating or inhibiting a symptom of a disease, disorder or condition associated with a topical pathogenic microorganism in a human subject, comprising administering to the human subject a composition formulated for topical application comprising an effective amount of human-derived Janthinobacterium lividum comprising the nucleic acid sequence consisting of SEQ ID NO: 5, wherein the topical pathogenic microorganism is selected from dermatophytes or gram-positive bacteria.
|